Tested immune therapy for certain HLA-A2 positive solid tumors
Treatments studied
Part of Cancer, Eyes & vision, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has come back, is getting worse, or cannot be cured with standard treatments
- Your body’s “activity level” score (ECOG) is 0 or 1
- Your tissue type test shows HLA-A*02:01 positive
- Your tumor must be able to be detected by the study test (IMADetect® RT-qPCR)
- You must have measurable disease on scans and be able to have blood and immune treatment as planned
- If you’re pregnant, breastfeeding, or unable to use contraception when required, you likely can’t join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune system treatment (IMA402) that is meant to help the body recognize and fight advanced solid tumors. It may be an option if your cancer has come back or did not respond to standard treatments, and if your overall health and tumor measurements meet study requirements.
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
This trial tests a treatment that takes immune cells from your tumor, multiplies them in a lab, and gives them back to you to fight the cancer. It is for people with advanced solid tumors who have tried other treatments or cannot have them.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Hear when a new Refractory Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.